- Home
- GMAB vs MOS Comparison
GMAB vs MOS Comparison
Compare GMAB & MOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- MOS
- Stock Information
- Founded
- GMAB 1999
- MOS 1987
- Country
- GMAB Denmark
- MOS United States
- Employees
- GMAB N/A
- MOS N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- MOS Agricultural Chemicals
- Sector
- GMAB Health Care
- MOS Industrials
- Exchange
- GMAB Nasdaq
- MOS Nasdaq
- Market Cap
- GMAB 13.7B
- MOS 11.2B
- IPO Year
- GMAB N/A
- MOS 2004
- Fundamental
- Price
- GMAB $21.88
- MOS $36.23
- Analyst Decision
- GMAB Buy
- MOS Buy
- Analyst Count
- GMAB 7
- MOS 12
- Target Price
- GMAB $37.80
- MOS $35.83
- AVG Volume (30 Days)
- GMAB 1.5M
- MOS 4.7M
- Earning Date
- GMAB 08-07-2025
- MOS 08-05-2025
- Dividend Yield
- GMAB N/A
- MOS 2.43%
- EPS Growth
- GMAB 276.80
- MOS N/A
- EPS
- GMAB 18.36
- MOS 1.15
- Revenue
- GMAB $3,230,902,140.00
- MOS $11,064,300,000.00
- Revenue This Year
- GMAB $747.74
- MOS $17.50
- Revenue Next Year
- GMAB $14.81
- MOS N/A
- P/E Ratio
- GMAB $1.19
- MOS $31.33
- Revenue Growth
- GMAB 25.43
- MOS N/A
- 52 Week Low
- GMAB $17.24
- MOS $22.36
- 52 Week High
- GMAB $28.56
- MOS $38.23
- Technical
- Relative Strength Index (RSI)
- GMAB 56.89
- MOS 52.59
- Support Level
- GMAB $21.10
- MOS $34.71
- Resistance Level
- GMAB $21.90
- MOS $36.64
- Average True Range (ATR)
- GMAB 0.39
- MOS 0.99
- MACD
- GMAB 0.11
- MOS -0.22
- Stochastic Oscillator
- GMAB 79.95
- MOS 43.18
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About MOS Mosaic Company (The)
Mosaic is one of the largest phosphate and potash producers in the world. The company's assets include phosphate rock mines in Florida, Brazil, and Peru and potash mines in Saskatchewan, New Mexico, and Brazil. Mosaic also runs a large fertilizer distribution operation in Brazil through its Mosaic Fertilizantes business.